CAR T-Cell Therapy for Mantle Cell Lymphoma: Tycel Jovelle Phillips, MD


The clinical associate professor from the Rogel Cancer Center at Michigan Medicine discussed the future of CAR T-cell therapy in mantle cell lymphoma patients.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Tycel Jovelle Phillips, MD, clinical associate professor, Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, about the future of CAR T-cell therapy in mantle cell lymphoma (MCL) patients.

Phillips discussed how CAR T-cell therapy appears to be agnostic to some of the high-risk features that distinguish frontline treatment outcomes in patients with MCL. As such, this modality may have clinical utility as up-front treatment to improve outcomes in patients with high-risk disease, Phillips explains. However, developing improved toxicity management, particularly with regard to CAR T-cell therapy–related neurotoxicity, is important in MCL, Phillips adds.

Increased exposure to using CAR T-cell therapy will increase provider comfortability with the modality and improve toxicity-management strategies, Phillips continues. With additional data emerging, FDA approvals of novel CAR T-cell therapies in MCL could be on the horizon to provide more options to patients, Phillips concludes.

Related Videos
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Related Content
© 2023 MJH Life Sciences

All rights reserved.